ALKS$34.53
$34.5359
Chart
Performance
Key Stats
AI ALKS Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyAlkermes presents a mixed but generally positive investment profile. Strong fundamental metrics related to profitability and cash flow are offset by a weaker near-term technical outlook and moderate thematic tailwinds. Suitable for investors seeking exposure to the biopharmaceutical sector with a focus on established product lines and a solid balance sheet.
Thematic
Alkermes operates in the biopharmaceutical sector, with key themes including treatments for neurological disorders and addiction. While its current product portfolio addresses significant unmet needs, the thematic growth potential is tempered by the competitive landscape and the need for continued pipeline development.
Fundamental
Alkermes demonstrates strong financial health, characterized by robust profitability, positive free cash flow, and a healthy balance sheet. While revenue growth has been variable, operational efficiency and profit conversion are commendable.
Technical
The stock is trading below key moving averages and shows bearish signals across multiple timeframes, indicating potential for further downside in the short term. While it has bounced off its 52-week low, the trend remains weak.
| Factor | Score |
|---|---|
| Biopharmaceuticals Market Growth | 70 |
| Drug Pipeline & Innovation | 60 |
| Therapeutic Area Focus | 75 |
| Competitive Landscape | 55 |
| Factor | Score |
|---|---|
| Valuation | 75 |
| Profitability | 90 |
| Growth | 40 |
| Balance Sheet Health | 95 |
| Cash Flow | 92 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 40 |
| Volume Confirmation | 60 |
| Support & Resistance | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (5)
Positive Earnings Surprises
The company has a track record of positive earnings surprises, exceeding analyst estimates in the last 3 out of 4 reported quarters, indicating operational efficiency and strong revenue generation.
Undervalued Relative to Growth
The P/E ratio of 12.633334 is relatively low given the company's earnings per share (EPS) of 2.1. The P/S ratio of 3.9 is moderate, suggesting potential undervaluation relative to sales.
Bearish Points (7)
Negative Short-Term Performance
The stock has experienced negative performance across multiple short-term periods, including -7.98% in the last month and -15.83% in the last 6 months, indicating recent investor sentiment is bearish.
High Price-to-Sales Ratio
The current P/S ratio of 3.9, while moderate in isolation, can be considered high for a biopharmaceutical company if future revenue growth does not materialize as expected. The company's historical P/S ratios show some variability.
Calendar
July 2025
29
Next Earnings Date
H: $0.47
A: $0.38
L: $0.29
H: 351.06M
A: 341.30M
L: 327.19M
Profile
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Seasonals
Price Target
41.44 USD
The 39 analysts offering 1 year price forecasts for ALKS have a max estimate of 54.00 and a min estimate of 30.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor with a strong focus on neurological, neurocrine, and psychiatric disorders, overlapping significantly with Alkermes's therapeutic areas.
Weight: 95
Direct competitor in the addiction treatment space, particularly for opioid and alcohol dependence, a core therapeutic area for Alkermes.
Weight: 90
Global pharmaceutical company exclusively focused on brain diseases, including psychiatric and neurological disorders, making it a direct thematic competitor.
Weight: 90
Strong presence in neuroscience, particularly sleep disorders (like narcolepsy), which is an emerging and significant pipeline area for Alkermes.